SEC Filing Summary: Predictive Oncology Inc. (POAI)
Business Context and Reporting Period
This Form 8-K was filed by Predictive Oncology Inc. on August 14, 2025. The report serves to announce the company's financial results for the quarter ended June 30, 2025, via a press release attached as Exhibit 99.1. The registrant is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol POAI.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are referenced as being contained within the attached press release (Exhibit 99.1) but are not present in the 8-K cover document itself.
Material Changes
No material changes versus the prior comparable period are detailed in this text. The filing solely acts as a notification of the release of quarterly results.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. Such information is expected to be found in the referenced press release.
Investor Verification Checklist
- Verify the specific revenue and net loss figures for the quarter ended June 30, 2025, by reviewing Exhibit 99.1 (Press Release).
- Confirm the company's cash position and burn rate as disclosed in the full financial statements.
- Review the press release for any updated guidance or changes in strategic direction.
- Note the signature by Josh Blacher, Interim Chief Financial Officer, indicating potential leadership transitions.